Search

everythinglearnresearchcommunity

for

Search:↓

Ritlecitinib helps regrow hair in people with alopecia totalis and universalis and is safe to use.

Targeted cancer therapies can cause skin side effects, which should be treated early to help patients' quality of life and treatment adherence.

Ritlecitinib provides new treatment options for diverse alopecia areata patients.

Hair regrowth treatments had modest benefits for patients with long-term hair loss after chemotherapy.

GBP1 is a key target for treating Epstein-Barr virus-related kidney cancer, and finasteride may help.

Finasteride may reduce prostate cancer risk.

New treatments for prostate cancer are less toxic and show promise, but more research is needed to enhance their effectiveness and reduce side effects.

EGFR inhibitors can cause unusual localized hair growth.

Ovarian Leydig cell tumors are hard to diagnose with just advanced imaging; expert ultrasound and clinical evaluation are essential.

Ritlecitinib improves hair regrowth satisfaction in alopecia areata patients.

Scalp cooling therapy helped over 80% of women keep at least half their hair during chemotherapy.

HPV genes and estradiol increase a cancer-related signaling pathway, which may be targeted for cervical cancer treatment.

Mitoxantrone with a corticosteroid helps manage symptoms for some advanced prostate cancer patients but doesn't extend life.

Immunotherapy with pembrolizumab significantly reduced cancer in a young woman with adrenocortical carcinoma.

Low-dose radiation therapy may improve brain function in some Alzheimer's patients and is generally well-tolerated.

Patients need better counseling and resources for managing chemotherapy-induced hair loss.

TQC shows promise for better hair regrowth in treating hair loss.

ALRV5XR effectively promotes hair regrowth in both men and women through different mechanisms.

Lokivetmab reduced itching in a dog with skin lymphoma.

Topical imiquimod use for treating a cervical lesion might cause delayed hair loss.

Disease-specific tools better assess alopecia areata's impact on quality of life.

The FFA-QLI is a reliable tool for assessing quality of life in women with severe Frontal Fibrosing Alopecia.

Deuruxolitinib effectively improves hair regrowth in alopecia areata but requires monitoring for side effects.

Ritlecitinib improves hair regrowth in alopecia areata over 24 months.

The session covered updates on skin treatments, including radiotherapy, imiquimod, acitretin, JAK inhibitors, and strategies for managing rosacea and preventing surgical infections.